Endoscopic Ultrasound Molecular Evaluation of Pancreatic Cancer Trial 2. A prospective cohort study to assess the utility of EUS-FNA supernatant for the comprehensive molecular profiling of advanced pancreatic cancer.

Monash Health Department of Upper GI Surgery0 个研究点目标入组 125 人开始时间: 2022年6月24日最近更新: 2022年8月9日

适应症

试验速览

暂无简介。

•1.Males or females with cytologically proven adenocarcinoma of the pancreas obtained by EUS-FNA. In those with ‘suspicious’ cytology, the diagnosis of pancreatic adenocarcinoma will be made in conjunction with supporting biochemical and radiological data
•2.Metastatic, locally advanced (based on the NCCN guidelines version 2, 2017 criteria) or recurrent disease
•3.EUS-FNA supernatant available for DNA/RNA extraction.
•4.Study participants must be at least 18 years of age at time of screening
•5.ECOG Performance Status 0-2
•6.Suitability for chemotherapy
•7.Able to give signed informed consent
•8.Life expectancy of at least 3 months from the time of screening as judged by screening investigator.
•9.Willingness to participate in the MoST program (ACTRN12616000908437)

•1.Patients considered to have operable or borderline resectable pancreatic cancer
•2.Patients with Neuroendocrine pancreatic cancers
•3.Evidence of systemic disease (cardiovascular, respiratory, renal, hepatic, etc.) that would preclude chemotherapy.
•4.Serious medical or psychiatric conditions that might compromise protocol-based management as judged by investigator

发起方

Monash Health Department of Upper GI Surgery